New York, New York--(Newsfile Corp. - September 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:
To view an enhanced version of this graphic, please visit:
To: All Persons or Entities who purchased Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU) stock prior to September 13, 2020.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Immunomedics toGilead Sciences, Inc. ("Gilead") (NASDAQ: GILD). Under the terms of the deal, Gilead will acquire Immunomedics for $88.00 per share in cash.To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
The Immunomedics merger investigation concerns whether the Board of Immunomedics has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63751